Scientific intelligence platform for AI-powered data management and workflow automation
Sample Size & Power Calculations
Calculate for a Variety of frequentist and Bayesian Design
Adaptive Design
Design and Analyze a Wide Range of Adaptive Designs
Milestone Prediction
Predict Interim Analysis Timing or Study Length
Randomization Lists
Generate and Save Lists for your Trial Design
Group Sequential and Promising Zone Designs
Calculate Boundaries & Find Sample Size. Evaluate Interim Data & Re-estimate Sample Size
Sample Size for Bayesian Statistics
Probability of Success (Assurance), Credible Intervals, Bayes Factors and more
Early Stage and Complex Designs
Sample size & operating characteristics for Phase I, II & Seamless Designs (MAMS)
Sample Size & Power Calculations
Calculate for a Variety of frequentist and Bayesian Design
Adaptive Design
Design and Analyze a Wide Range of Adaptive Designs
Milestone Prediction
Predict Interim Analysis Timing or Study Length
Randomization Lists
Generate and Save Lists for your Trial Design
Group Sequential and Promising Zone Designs
Calculate Boundaries & Find Sample Size. Evaluate Interim Data & Re-estimate Sample Size
Sample Size for Bayesian Statistics
Probability of Success (Assurance), Credible Intervals, Bayes Factors and more
Early Stage and Complex Designs
Sample size & operating characteristics for Phase I, II & Seamless Designs (MAMS)
Effective and Efficient Drug Development
Dr. Luis Rojas, the Executive Director Head of Biostatistics at Target Health, is a subject matter expert in study design and sample size calculations with more than 30 years of industry experience.
He has worked in the leading CROs in the industry and has assisted pharmaceutical companies with the drug development process with clinical trials, programs, and portfolio designs. His experience extends from preclinical, phases I through IV, biosimilar, and bioequivalent using fixed, adaptive designs, stand-alone, and master protocols in multiple therapeutic areas.
Today this work presents new challenges. Drug pipelines are larger than ever before, while the cost of bringing new drugs to market has nearly doubled in the past decade. This trend has compressed drug development ROIs and increased competition
“nQuery is a one-stop platform. It is 100% reliable for me,” said Dr Rojas. “If the user knows the study design that needs to be implemented, then sample size calculation is a question of just minutes. Trying to programmatically do the same calculations in SAS or R usually takes more than 20 times longer. nQuery’s documentation is very helpful and provides very clear guidance to understand and implement the calculations that you need to perform. Side tables in most sample size modules make the process even easier.”nQuery is a one-stop platform. It is 100% reliable for me.
Dr Luis Rojas,
Executive Director Head Of Biostatistics At Target Health
With increasing costs, competition, and risk, adaptive clinical trials have made rapid headway as a method to alleviate these challenges. Adaptive trials enable continual modification to the trial design based on interim data. This means that with adaptive trials, you have the opportunity to make changes to your trial, while it is still ongoing. Within nQuery, the world’s most trusted clinical trial design platform, there is a dedicated module for adaptive clinical trials that provide biostatisticians with a range of tools across various adaptive disciplines for sample size calculation.
That’s why Dr. Rojas is a proponent of nQuery to serve as a reliable digital tool for sample size calculations in adaptive and fixed trials.
Leveraging nQuery, Dr. Rojas has developed hundreds of clinical trials and programs.
Copyright © Statsols. All Rights Reserved. Do Not Sell or Share My Personal Information | Privacy Policy | License Agreement | Legal Disclaimers